Abstract:
Objective
To observe the clinical effect of recombinant human growth hormone (rhGH) in the treatment of growth hormone deficiency(GHD) and idiopathic short stature (ISS) in children, and to explore the value and safety of IGF-1.
Methods
A total of 12 GHD children and 7 ISS children diagnosed in Yixing People Hospital from January 2016 to December 2017 were chosen as the research subjects and were treated with rhGH. They were divided into GHD group and ISS group according to the diagnosis. Subcutaneous injection of rhGH at 0.1-0.2 U/（kg·d） was given 30 min before going to bed for 6-7 times each week. The growth rate and IGF-1 were measured before treatment, and at 3 months and 6 months after treatment. The standard deviation integral was calculated, too.
Results
(1) The average height increase and growth rate in GHD group were significantly higher than those in ISS group, and the difference was statistically significant.(2) The standard deviation integral of IGF-1 in both groups increased significantly, with statistical significance, and the increase in GHD group was significantly higher than that in ISS group.
ConclusionRhGH has obvious effect of promoting growth on children with short stature, especially on children with GHD, and IGF-1 is helpful for the evaluation of efficacy and safety.

Key words: Growth hormone deficiency, Idiopathic short stature, IGF-1, Recombinant human growth hormone, Child